The protein disulfide isomerase A3 and osteopontin axis promotes influenza‐induced lung remodelling
British Journal of Pharmacology · 2024-11 · 181 (22) · 4610-4627
DOI: 10.1111/bph.16511 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Pharmacology, online erschienen am 08.08.2024. Verfasst von Amit Kumar und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, Larner College of Medicine, The University of Vermont, Burlington, Vermont, USA. Hauptthemen laut MEDLINE: Protein Disulfide-Isomerases, Osteopontin, Lung. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NHLBI NIH HHS, NIH HHS, NCATS NIH HHS.
Abstract (Originalsprache)
Background and Purpose Fibrotic lung remodelling after a respiratory viral infection represents a debilitating clinical sequela. Studying or managing viral–fibrotic sequela remains challenging, due to limited therapeutic options and lack of understanding of mechanisms. This study determined whether protein disulfide isomerase A3 (PDIA3) and secreted phosphoprotein 1 (SPP1), which are associated with pulmonary fibrosis, can promote influenza‐induced lung fibrotic remodelling and whether inhibition of PDIA3 or SPP1 can resolve viral‐mediated fibrotic remodelling. Experimental Approach A retrospective analysis of TriNetX data sets was conducted. Serum from healthy controls and influenza A virus (IAV)‐infected patients was analysed. An inhibitor of PDIA3, punicalagin, and a neutralizing antibody for SPP1 were administered in mice. Macrophage cells treated with macrophage colony‐stimulating factor (M‐CSF) were used as a cell culture model. Key Results The TriNetX data set showed an increase in lung fibrosis and decline in lung function in flu‐infected acute respiratory distress syndrome (ARDS) patients compared with non‐ARDS patients. Serum samples revealed a significant increase in SPP1 and PDIA3 in influenza‐infected patients. Lung PDIA3 and SPP1 expression increased following viral infection in mouse models. Punicalagin administration 2 weeks after IAV infection in mice caused a significant decrease in lung fibrosis and improved oxygen saturation. Administration of neutralizing SPP1 antibody decreased lung fibrosis. Inhibition of PDIA3 decreased SPP1secretion from macrophages, in association with diminished disulfide bonds in SPP1. Conclusion and Implications The PDIA3–SPP1 axis promotes post‐influenza lung fibrosis in mice and that pharmacological inhibition of PDIA3 or SPP1 can treat virus‐induced lung fibrotic sequela.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology and Laboratory Medicine, Larner College of Medicine, The University of Vermont, Burlington, Vermont, USA.
- Division of Pulmonary Disease and Critical Care Medicine, Department of Medicine, Larner College of Medicine, The University of Vermont, Burlington, Vermont, USA.
- Division of Pulmonary Medicine, Allergy, and Immunology, Department of Pediatrics, Children's Hospital of Pittsburgh of UPMC, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
- Department of Pulmonary, Critical Care and Sleep Medicine, Yale University, New Haven, Connecticut, USA.
- Division of Biomedical Informatics, Cincinnati Children's Hospital Medical Center, Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
- Department of Computer Science, University of Cincinnati College of Engineering and Applied Science, Cincinnati, Ohio, USA.
Förderung
- NHLBI NIH HHS
- NIH HHS
- NCATS NIH HHS
- NIAID NIH HHS
- National Institutes of Health
Zitieren
APA
Kumar, A., Mark, Z. F., Carbajal, M. P., DeLima, D. S., Chamberlain, N., Walzer, J., Ruban, M., Chandrasekaran, R., Daphtary, N., Aliyeva, M., Poynter, M. E., Janssen-Heininger, Y. M. W., Bates, J. H., Alcorn, J. F., Britto, C. J., Dela Cruz, C. S., Jegga, A. G., & Anathy, V. (2024). The protein disulfide isomerase A3 and osteopontin axis promotes influenza‐induced lung remodelling. British Journal of Pharmacology, 181(22), 4610-4627. https://doi.org/10.1111/bph.16511
Vancouver
Kumar A, Mark ZF, Carbajal MP, DeLima DS, Chamberlain N, Walzer J, et al. The protein disulfide isomerase A3 and osteopontin axis promotes influenza‐induced lung remodelling. British Journal of Pharmacology. 2024;181(22):4610-4627. doi:10.1111/bph.16511
BibTeX
@article{Kumar2024,
author = {Kumar, Amit and Mark, Zoe F and Carbajal, Morgan P and DeLima, Dhemerson Souza and Chamberlain, Nicolas and Walzer, Joseph and Ruban, Mona and Chandrasekaran, Ravishankar and Daphtary, Nirav and Aliyeva, Minara and Poynter, Matthew E and Janssen-Heininger, Yvonne M W and Bates, Jason H and Alcorn, John F and Britto, Clemente J and Dela Cruz, Charles S and Jegga, Anil G and Anathy, Vikas},
title = {The protein disulfide isomerase A3 and osteopontin axis promotes influenza‐induced lung remodelling},
journal = {British Journal of Pharmacology},
year = {2024},
volume = {181},
number = {22},
pages = {4610--4627},
doi = {10.1111/bph.16511}
}
EUVIMED